Assessing the role of ADAM10 in Trastuzumab treatment and resistance
<p>Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback...
Autor principal: | Feldinger, K |
---|---|
Altres autors: | Kong, A |
Format: | Thesis |
Idioma: | English |
Publicat: |
2012
|
Matèries: |
Ítems similars
-
Functional organisation of the Hrd1 ubiquitin ligase complex and its role in ERAD
per: Schulz, J
Publicat: (2013) -
The role and regulation of Asterless in the centrosome cycle
per: Novak, ZA
Publicat: (2014) -
Characterisation of AEBP2: a polycomb repressive complex 2 component
per: Grijzenhout, A
Publicat: (2013) -
Cell stress response and hypoxia in breast cancer
per: Milani, M, et al.
Publicat: (2011) -
Nitric oxide: a chemical effector of pathogenesis in magnaporthe oryzae
per: Johnson, J
Publicat: (2011)